Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Telomir-Zn
- Development stage
- Phase 2
- Lead developer
- Telomir Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Telomir-Zn is an oral small molecule therapeutic developed by Telomir Pharmaceuticals, representing the formulated version of the lead candidate Telomir-1 (also known as Zn-Telomir). It functions by modulating intracellular metal homeostasis, specifically reducing labile redox-active iron and copper while increasing the availability of bioavailable zinc. This metal modulation targets epigenetic enzymes within the lysine demethylase (KDM) families, which are critical regulators of oxidative stress, DNA methylation, and genomic stability. Preclinical research has demonstrated its potential in treating various cancers—including triple-negative breast cancer, prostate cancer, pancreatic cancer, and leukemia—as well as addressing aging and degenerative diseases. Unlike traditional cytotoxic agents, Telomir-Zn exerts its effects through iron-dependent pathways and the regulation of histone and DNA methylation.
- Other names
- Telomir-1Telomir1Telomir 1Zn-Telomir
02
Targets
Zn2+ (Zinc ion)Fe2+ (Ferrous iron)
Beyond the preview
Go deeper on Telomir-Zn.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Telomir-Zn.